KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Liabilities from Discontinued Operations Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Bristol Myers Squibb (BMY) Land & Improvements (2025 - 2026)

Bristol Myers Squibb has reported Land & Improvements over the past 2 years, most recently at $157.0 million for Q1 2026.

Quarterly Land & Improvements changed N/A to $157.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $157.0 million through Mar 2026, changed N/A year-over-year, with the annual reading at $157.0 million for FY2025, N/A changed from the prior year.
Land & Improvements was $157.0 million for Q1 2026 at Bristol Myers Squibb, roughly flat from $157.0 million in the prior quarter.
Over five years, Land & Improvements peaked at $157.0 million in Q4 2025 and troughed at $157.0 million in Q4 2025.